Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

73
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
73
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

16
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
16
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

87
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
87
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

303
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
303
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

22
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
22
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UK.

The International journal on drug policy·2026
Same author

Correction: Hepatitis C virus cascade of care among adults in Sindh province, Pakistan: Findings from 2019-2020 household sero-survey.

PLOS global public health·2026
Same author

The Impact of Hepatitis C and Socio-Demographic Variables on Health-Related Quality of Life in Pakistan: Cross-Sectional Study.

Journal of viral hepatitis·2026
Same author

The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling.

Health technology assessment (Winchester, England)·2026
Same author

Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: a systematic review and meta-analysis.

BMC infectious diseases·2025
Same author

Evaluating hepatocellular carcinoma (HCC) surveillance through an early diagnostic centre: An implementation science approach at a tertiary hepatology centre in England.

Clinical medicine (London, England)·2025
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Understanding challenges to prevention of healthcare related infections.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Apr 22, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K

Hepatitis C genotype 1.

Graham R Foster1, Sampath De Silva

  • 1Barts and The London School of Medicine, London, United Kingdom.

Current Opinion in Infectious Diseases
|October 12, 2014
PubMed
Summary
This summary is machine-generated.

Hepatitis C treatment has rapidly advanced, with new interferon-free regimens offering over 90% cure rates. These highly effective treatments promise shorter durations and fewer side effects for patients with hepatitis C virus.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.4K

Related Experiment Videos

Last Updated: Apr 22, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

11.2K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.4K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection remains a significant global health concern.
  • Genotype 1 (G1) HCV is the most prevalent form worldwide.
  • Traditional interferon-based therapies are associated with significant side effects and variable efficacy.

Purpose of the Study:

  • To review recent advancements in genotype 1 hepatitis C virus treatment.
  • To focus on the development and efficacy of novel interferon-free treatment regimens.

Main Methods:

  • Systematic review of recent clinical trials and therapeutic guidelines.
  • Analysis of efficacy, tolerability, and duration of new treatment regimens.
  • Assessment of response rates across diverse patient populations.

Main Results:

  • Newer interferon-containing regimens show improved tolerability.
  • Interferon-free regimens demonstrate outstanding efficacy, with response rates exceeding 90%.
  • These novel regimens offer shorter treatment durations (8-12 weeks) and improved side-effect profiles.

Conclusions:

  • Hepatitis C treatment has been revolutionized, significantly improving patient outcomes.
  • Interferon-free regimens represent a paradigm shift, offering a potential cure for most patients.
  • Reduced morbidity and mortality associated with HCV infection are anticipated with widespread adoption of new therapies.